OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb
CA043-001
Phase 2 small_molecule active
Quick answer
OPDIVO 10 mg/mL concentrate for solution for infusion., Stivarga 40 mg film-coated tablets, anti-CTLA-4 NF Probody® mAb for Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)). is a Phase 2 program (small_molecule) at Bristol-Myers Squibb / Pfizer EEIG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Bristol-Myers Squibb / Pfizer EEIG
- Indication
- Advanced solid tumors (squamous cell carcinoma of the head and neck (SCCHN), non-small cell lung cancer (NSCLC), cutaneous melanoma, triple-negative breast cancer (TNBC), renal cell carcinoma (RCC), urothelial carcinoma, gastric, esophageal, cervical, and colorectal cancer (CRC)).
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active